Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 13/20 | 0.74 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.72 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6360792 | 0.99 | MAPKAPK2 (0.73) | MAPKAPK2MAPKAPK5SIRT1RECQLSIRT2 | |
| SCHEMBL14924843 | 0.86 | MAPKAPK2 (0.77) | MAPKAPK2MAPKAPK5SIRT1RECQLSIRT2 | |
| SCHEMBL6240174 | 0.85 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5SIRT1HTR2AHTR2C | |
| SCHEMBL6240455 | 0.84 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5SIRT1HTR2AHTR2C | |
| SCHEMBL6239981 | 0.84 | MAPKAPK2 (0.74) | MAPKAPK2MAPKAPK5SIRT1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL6236292 | 0.84 | MAPKAPK2 (0.97) | MAPKAPK2MAPKAPK5HTR2AHTR2C | |
| SCHEMBL6245012 | 0.84 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5SIRT1HTR2AHTR2C | |
| SCHEMBL11491192 | 0.84 | MAPKAPK2 (0.66) | MAPKAPK2MAPKAPK5SIRT1HTR2AHTR2C | |
| SCHEMBL12660570 | 0.84 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5SIRT1HTR2B | |
| SCHEMBL6235224 | 0.84 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5SIRT1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005009370-A2 | BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | MAPKAPK2 2180/4885MAPKAPK5 1542/4885SIRT1 69/4885 |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885MAPKAPK5 34/4885SIRT1 1037/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | MAPKAPK2 4562/4885MAPKAPK5 4524/4885SIRT1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.